Latest Report Overview for Doximity Inc ($DOCS)
AI-powered analysis of Doximity Inc (DOCS) stock based on Q4 2025 financial data.
Latest Report Overview
Doximity Inc $DOCS reported financial results for the third quarter of fiscal year 2026, ending December 31, 2025. The company generated quarterly revenue of $185.1 million, representing a 10% year-over-year increase. Net income for the quarter was $61.6 million, with an operating margin of approximately 38.9%. As of December 31, 2025, the company maintained a strong balance sheet with $64.8 million in cash and cash equivalents and $670.3 million in marketable securities, with no debt. Business performance was driven by continued strength in subscription-based services, which accounted for approximately 95% of total revenue. The company continued to scale its high-value customer base, with 126 customers contributing at least $500,000 in trailing 12-month subscription revenue, compared to 115 in the prior period. Net revenue retention remained strong at 112%. Operational expenses increased as the company continued to invest in research and development and personnel, partially offset by high gross margins of approximately 90%. Management commentary emphasized the ongoing investment in AI-driven workflow tools and the strategic integration of recent acquisitions like Pathway Medical. The company confirmed a settlement of the previously disclosed class action securities lawsuit for $31 million, which is covered by insurance. Furthermore, management remains focused on capital allocation, recently authorizing an additional $500 million share repurchase program on February 3, 2026, building upon the previous $500 million authorization.
Key Takeaways for Doximity Inc
- Doximity entered a settlement to resolve the class action securities lawsuit on December 24, 2025, agreeing to a $31 million payment which is fully covered by insurance.
- The company continues to aggressively return capital, authorizing an additional $500 million share repurchase program on February 3, 2026, following the near-completion of the prior $500 million program.
- Revenue growth remains solid, with 10% YoY increase in fiscal Q3 2026 and 16% YoY growth for the first nine months of the fiscal year.
- High-value customer penetration continues, with 126 customers contributing >$500k in TTM subscription revenue, up from 115 in the prior year.
- Litigation with OpenEvidence Inc. (filed June 2025) remains active, with the court dismissing some claims but denying motions to dismiss others in January 2026.
- Pathway Medical acquisition (July 2025) integration is ongoing, with significant R&D investment focused on AI capabilities.
- Profitability remains high, with adjusted EBITDA of $111.4 million in Q3, demonstrating sustained operational leverage.